Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy
Keywords: aAPC; artificial antigen-presenting cells; αGalCer; α-galactosylceramide; ACT; adoptive cell transfer; ADCC; antibody-dependent cell-mediated cytotoxicity; ALL; Acute Lymphoblastic Leukemia; AML; acute lymphoid leukemia; CAR; chimeric antigen receptor;